Meeting to be held in London and Zurich on March 31-April 2 hosted by Cantor Fitzgerald.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves
- Zevra Therapeutics price target raised to $22 from $20 at Guggenheim
- Zevra Therapeutics: Promising Outlook with Strong Financials and Strategic Focus on Rare Diseases
- Zevra Therapeutics price target raised to $25 from $23 at Canaccord
- Zevra Therapeutics: Strong Buy Rating Backed by Impressive Sales and Robust Financial Position